SPY415.87+4.42 1.07%
DIA340.44+2.91 0.86%
IXIC14,038.76+180.92 1.31%

RBC Capital Maintains Outperform on Osmotica Pharmaceuticals, Lowers Price Target to $8

RBC Capital analyst Randall Stanicky maintains Osmotica Pharmaceuticals (NASDAQ:OSMT) with a Outperform and lowers the price target from $12 to $8.

· 03/17/2021 07:55
RBC Capital analyst Randall Stanicky maintains Osmotica Pharmaceuticals (NASDAQ:OSMT) with a Outperform and lowers the price target from $12 to $8.